

1 **Polydimethylsiloxane loaded capsaicin afflicts membrane integrity, metabolic activity and**
2 **biofilm formation of nosocomial pathogens**

3 Alwar Ramanujam Padmavathi^{1,2}, Karthikeyan B³, Toleti Subba Rao^{1,2}, Senthil Kumar J⁴ and P.
4 Sriyutha Murthy^{1,2*}

5
6 ¹Biofouling and Biofilm Processes Section, Water and Steam Chemistry Division, Bhabha
7 Atomic Research Centre Facilities, Kalpakkam 603 102, India.

8 ²Homi Bhabha National Institute, Anushaktinagar, Mumbai 400 094, India.

9 ³Department of Biotechnology, Sri Krishna Arts and Science College, Coimbatore - 641008,
10 India.

11 ⁴Department of Biotechnology, PSG College of Arts & Science, Coimbatore -641014, India

12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29

****Corresponding author***

Dr. P. Sriyutha Murthy

Tel: +91 44 27480500 -Extension: 23636

Fax: +91 44 27480097

Email: psmurthy@igcar.gov.in, sriyuthamurthy@yahoo.in

ORCID ID <https://orcid.org/0000-0002-6555-953X>

30 **Abstract:**

31 Biofilms constitute 80% of all nosocomial infections associated with invasive medical devices.
32 Polydimethylsiloxane, a silicone polymer widely used as implants, suffers from microbial
33 adhesion. Inhibition of biofilm formation on PDMS surfaces is significant to prevent morbidity,
34 mortality and replacement. The present study investigates the efficacy of capsaicin (0.5% w/v)
35 loaded PDMS as a broad spectrum antimicrobial surface against *Staphylococcus aureus*,
36 *Escherichia coli* and *Candida albicans*. Capsaicin exhibited minimum inhibitory concentration
37 (MIC) of 1024 $\mu\text{g mL}^{-1}$ for *S. aureus*, *E. coli* and 256 $\mu\text{g mL}^{-1}$ for *C. albicans*. Capsaicin
38 inhibited biofilms of *S. aureus*, *E. coli* and *C. albicans* at much lower concentrations of 2, 64 and
39 8 $\mu\text{g mL}^{-1}$ respectively. The minimum capsaicin concentrations required for total biofilm
40 eradication (MBEC) was found to be 256, 512, 128 $\mu\text{g mL}^{-1}$ for *S. aureus*, *E. coli* and *C. albicans*
41 respectively. Probing sub-lethal concentrations (64 $\mu\text{g mL}^{-1}$) of capsaicin revealed 38, 32, 30%
42 reduction in metabolic activity of *S. aureus*, *E. coli* & *C. albicans* planktonic cells respectively.
43 Similarly, there was an increase in permeability of cells to propidium iodide compared to control.
44 By reducing the metabolic activity and perturbing membrane integrity, capsaicin could prevent
45 biofilm formation and this was also observed with capsaicin-PDMS surfaces that exhibited 1 log
46 (~90%) reduction of viable bacterial counts.

47

48 **Keywords:** Capsaicin, Polydimethylsiloxane, antibiofilm, Membrane damage, nosocomial
49 pathogens.

50

51

52

53

54

55

56

57

58

59 1. Introduction

60 Polydimethylsiloxane (PDMS) is a silicone polymer widely used in various fields such as
61 microfluidics, optics, electronics, biology, medicine, energy, etc. PDMS based devices/surfaces
62 are increasingly used as implants/biomaterial due to their superior biocompatibility, non-
63 immunogenicity, biomechanical behaviour such as flexibility, chemical stability, resistance and
64 inert properties. PDMS has been used as versatile scaffold, prostheses and implants at 20
65 different points in the human body such as spinal implants, voice prosthesis, cochlear implants,
66 hybrid dental implants, drug delivery devices, breast implant coatings, urinary catheters etc,
67 [1,2]. However due to its hydrophobic nature, PDMS surfaces are prone to microbial adhesion
68 and subsequent biofilm formation [3]. Biofilms are hard to eradicate compared to their
69 planktonic counterparts due to their different phenotype, gene expression, protein synthesis and
70 production of viscous exopolymeric substance [4].

71 It is also obvious that any implanted object which is prone to biofilm development can
72 compromise patient safety and material functionality [1],[5]. Several control strategies have been
73 developed to impart antimicrobial property to the implant material which can minimise biofilm
74 formation and subsequent infections. Biofilm formation on implant material is attributed to the
75 reduced host immune response, besides implants offer an interface for microbial adhesion and
76 growth [6]. The major dominant microbes on implants and prosthetic devices are *Staphylococcus*
77 *aureus*, *Escherichia coli* and *Candida albicans*. *S. aureus* is known to cause very serious
78 infections such as ventilator associated pneumonia, orthopaedic and breast implant infections,
79 cardiac device infections and infective endocarditis of prosthetic aortic and mitral valves, etc.
80 [7]. Uropathogenic *E. coli* causes symptomatic urinary tract infections (UTI) as well as
81 asymptomatic bacteriuria. *E. coli* occurs on prosthetic joints, shunts, grafts and causes
82 bacteraemia and sepsis [8]. Bacterial contamination of Intravenous (IV) and urethral catheters
83 cost approximately \$300 million to \$2.3 billion annually [5]. Fungal infections caused by
84 *Candida* spp. account for over 400,000 per year. *C. albicans* can form biofilms on various
85 implants such as cochlear, dental, hip implants, contact lenses, silicone and polyurethane
86 catheters and attributed to healthcare associated infections [9].

87 Impregnating polymers with antimicrobials and their release over time has gained more
88 importance recently. In this direction, antimycotics incorporated into PDMS were developed to

89 inhibit *C. albicans* [10]. Recent studies have shown that *Candida* spp. have developed wide
90 range of resistance mechanism to antimycotics and also cross resistance mechanisms between
91 species. *Candida* spp. related biofilm infections have high mortality rate of around 41%.
92 Currently different species of *Candida* have developed resistance to conventional antimycotics
93 viz: polyenes, azoles, echinocandins, 5-flucytocine. This has warranted the search for alternate
94 antimicrobial agents. It is imperative to follow antibiofilm approaches to effectively culminate
95 device associated infections. Antibiofilm approaches for polymeric implants / prosthesis like
96 PDMS, involve incorporation of nitric oxide releasing xerogel coatings; enzymes; antibiotics,
97 nanoparticles, surface modifications, etc to improve their antimicrobial properties [2,11].
98 However, most of these studies have demonstrated antibacterial activity under *in vitro* conditions
99 and elicit biocompatibility issues for *in situ* applications. Hence there is a search for a less
100 cytotoxic, more biocompatible, antimicrobial agent.

101 In comparison, capsaicin (8-methyl-N-vanilyl-6-nonenamide) possesses all the required
102 attributes such as biocompatibility, excellent antibacterial properties, approved for topical use,
103 which makes it a viable, safe and low cost alternative antimicrobial for implant material.
104 Capsaicin, a pungent compound of chilli pepper, has topical pharmaceutical application in
105 rheumatoid arthritis, osteoarthritis and diabetic neuropathy. Capsaicin has anticancer activity by
106 targeting signalling pathways that regulates oncogenes and tumour suppressor genes [12].
107 Capsaicin has been found to possess prolonged release and good bioavailability in topical gel
108 formulations [13]. Several studies have reported the *in vitro* antimicrobial property of capsaicin
109 [14,15]. Capsaicin also inhibited the NorA efflux pumps in *S. aureus* by reducing its intracellular
110 invasion ability [16] and demonstrated synergistic antibacterial activity in combination with
111 antibiotics [17]. Capsaicin has been shown to possess antibiofilm and biofilm dispersal
112 properties [18]. Capsaicin loaded into different polymers as fillers has shown excellent anti-algal
113 and marine antifouling property [19,20]. The present study aims at evaluating the antimicrobial
114 activity of capsaicin on planktonic and biofilms of three (*S. aureus*, *E. coli* and *C. albicans*) most
115 common nosocomial pathogens and their mechanism of action. This study also evaluates the
116 efficacy of PDMS loaded capsaicin surfaces *in vitro*.

117 **2. Materials & Methods**

118 **2.1. Microbial strains and growth conditions**

119 *S. aureus* (V329) and *E. coli* (ATCC 10536) were grown in Tryptic soy broth (TSB)
120 supplemented with 0.25% glucose and Luria Bertani (LB) broth respectively at 37°C in an orbital
121 shaker at 160 rpm to mid log phase. *C. albicans* (ATCC 90028) was maintained in potato
122 dextrose broth/ agar (PDB/PDA) in an orbital shaker at 37 ± 1°C. Spider broth (0.2% K₂HPO₄,
123 1% mannitol, 0.005% beef extract, 0.01% peptone and 0.01% NaCl) was used for filamentous
124 growth.

125 **2.2. Evaluation of Minimum inhibitory and microbicidal concentrations of capsaicin**

126 Minimum inhibitory concentration (MIC) and Minimum Bactericidal concentration (MBC) of
127 capsaicin (Sigma-Aldrich) against planktonic cells of *S. aureus* and *E. coli* were determined
128 using 96 well microtitre plates. MIC and Minimum fungicidal concentration (MFC) were also
129 determined against *C. albicans* planktonic cells [21]. Varying concentrations of capsaicin (1024,
130 512, 256, 128, 64, 32, 16, 8, 4 & 2 µg mL⁻¹) were achieved by microdilution from the stock of
131 4096 µg mL⁻¹ capsaicin in ethanol and appropriate vehicle controls were followed. The overnight
132 grown cultures were adjusted to ~10⁵ CFU mL⁻¹ using UV-vis spectrophotometer (Shimadzu,
133 uv-1601, Japan) at 600 nm, added as initial inocula and the assay volume was fixed as 200 µL
134 per well. Respective media alone served as blank and media with inoculum served as controls.
135 The plates were incubated for 24 h for growth in a temperature controlled incubator at 37°C ±
136 1°C. The MIC, MBC and MFC values were determined from optical density measurements at
137 600 nm using a multi-mode reader (BIOTEK-SYNERGY, India). MBC and MFC were
138 confirmed by plating on respective agar where there was no colony observed. The percentage
139 inhibition of planktonic cell growth was calculated using the formulae

$$140 \quad \% \text{ Inhibition} = [(Control \text{ OD}_{600} - \text{treated OD}_{600}) / Control \text{ OD}_{600}] \times 100$$

141 **2.3. Planktonic cell metabolic activity – XTT Reduction assay**

142 The metabolic status of control planktonic cells and cells exposed to sub-MICs of capsaicin (64,
143 128 µg mL⁻¹) was evaluated using the XTT [2, 3-bis (2-methoxy-4-nitro-5-sulfophenyl)-2H-
144 tetrazolium-5-carboxanilide sodium salt] reduction assay. The cell suspensions were prepared by
145 centrifuging 1 mL of control and treated cells and the pellets were adjusted to 0.5 OD using PBS.
146 Briefly 200 µL of XTT (0.2 mg mL⁻¹ in 1X PBS) and menadione (0.172 mg mL⁻¹ in acetone)
147 were mixed in a ratio of 25:1 and added to 200 µL of planktonic cell suspension and incubated at
148 37°C for 3 h in dark. The coloured supernatant containing XTT formazan was transferred to new

149 microtitre plates and measured at 490 nm [22]. Percentage of inhibition in metabolic activity was
150 calculated as described below.

$$151 \quad \% \text{ Inhibition} = [(\text{Control OD}_{490} - \text{treated OD}_{490}) / \text{Control OD}_{490}] \times 100$$

152 **2. 4. Propidium Iodide uptake and membrane damage of planktonic cells**

153 Propidium iodide (PI) uptake is used as a tool to assess membrane damage. PI is a fluorescent
154 probe binds to nucleic acids producing a red fluorescence in cells with compromised cell
155 membranes. A 10 μM working solution of PI (Molecular probes®, Invitrogen) was prepared in
156 1X PBS and stored in dark at 4°C. 200 μL of control and sub-lethal concentrations of capsaicin
157 (64, 128 $\mu\text{g mL}^{-1}$) treated planktonic cell suspensions prepared as mentioned above were stained
158 with 200 μL of PI and incubated for 10 min in dark. The cells were then washed with sterile PBS
159 to remove excess PI and re-suspended in PBS. The relative fluorescence intensity units (RFU)
160 were measured using a Biotek-Synergy Multimode reader with an excitation and emission of 530
161 nm and 620 nm respectively [23].

162 **2. 5. Evaluation of antibiofilm activity of capsaicin**

163 After evaluation of MIC and MBC of planktonic cultures, the 96 well plates were quantified for
164 biofilms formed in the presence of varying concentrations of capsaicin (1024, 512, 256, 128, 64,
165 32, 16, 8, 4, 2 & 0 $\mu\text{g mL}^{-1}$). The planktonic cultures were discarded and the wells were washed
166 with sterile 1X PBS (pH=7.4) to remove any loosely adhered cells and stained with 200 μL of
167 0.1 % crystal violet (CV) for 5 min [23]. Crystal violet solution was then discarded and the plates
168 were washed twice with PBS to remove any unbound CV and the plates were air dried.
169 Subsequently 200 μL of glacial acetic acid (33 %) was added to each of the wells to solubilise
170 the cell bound CV for 10 min and optical density was measured at 570 nm. The minimum
171 concentration of capsaicin required to inhibit maximum biofilm formation was identified as the
172 biofilm eradication concentration (MBEC) from the values. The percentage of biofilm inhibition
173 was calculated using the following formula.

$$174 \quad \% \text{ Inhibition} = [(\text{Control OD}_{570} - \text{treated OD}_{570}) / \text{Control OD}_{570}] \times 100$$

175 **2. 6. Microscopic Evaluation of effect of capsaicin on biofilms**

176 Effect of various concentrations (64, 128, 256, 512 and 1024 $\mu\text{g mL}^{-1}$) of capsaicin on biofilm
177 formation of test pathogens was investigated using epifluorescence microscope [23]. The assay

178 was performed in a polystyrene 24 well plate. The test pathogens were allowed to form biofilm
179 in a 1 X 1 cm glass surface in the presence of capsaicin at 37°C for 24 h. Control biofilms were
180 formed in the absence of capsaicin. After 24 h incubation, the planktonic cells were discarded
181 and glass slides were rinsed with sterile PBS to remove loosely adhered cells. The glass slides
182 containing biofilms were stained with BacLight™ Live/dead staining solution (L13152-
183 Molecular Probes, Invitrogen) and observed under epifluorescence microscope.

184 **2. 7. Preparation & characterization of capsaicin loaded PDMS surfaces**

185 PDMS surfaces were prepared from Sylgard 184 (DOW Corning, Midland, MI) by mixing the
186 base polymer (A) and the curing agent (B) in a ratio of 10:1 [23]. Capsaicin (0.5% w/v) was first
187 added to the curing agent (B) and kept in an ultra sonicator bath (frequency 33 ± 3 kHz), for 15
188 min for uniform dispersion. Then part B was mixed with part A and vortexed for 15 min for
189 uniform dispersion into the matrix. The mixture was then degassed to remove air bubble in a
190 vacuum desiccator for 30 min. The solutions were poured into glass trays and allowed to
191 vulcanize at room temperature overnight, to prepare free standing PDMS films. Plain PDMS
192 surfaces without capsaicin were also prepared.

193 **2. 8. Evaluation of *in vitro* antibiofilm activity of capsaicin loaded PDMS**

194 Plain PDMS control surfaces as well as capsaicin loaded PDMS surfaces were cut into the size of
195 2 x 2 cm in triplicates and were UV sterilized for 30 min prior to performing assay. Biofilm
196 inhibition assays were conducted in 6 well polystyrene plates using 5 mL of TSB for *S. aureus*,
197 LB for *E. coli* and spider broth for *C. albicans*. 500 µl of 0.05 OD ($\sim 10^5$ CFU mL⁻¹) adjusted
198 cultures were inoculated and the plates were incubated at 37°C for 24 h in a temperature
199 controlled incubator. After 24 h of incubation, the polymer films were taken out and rinsed with
200 sterile PBS to remove loosely adhered cells and was stained with Live/Dead BacLight® stain for
201 2 min. Excess stain was rinsed with sterile PBS. The surfaces were visualized under an
202 epifluorescence microscope (Axioscope-I, Carl Zeiss, Germany), using FITC (SYTO 9) and
203 dsRed (Propidium Iodide) filters for green and red fluorescence respectively. Live cells appear
204 green and dead cells appear red in colour. Parallely another set of similar surfaces were
205 incubated and after 24 h the PDMS surfaces were collected into centrifuge tubes containing
206 sterile PBS (10 mL). The surfaces were ultra-sonicated (10 min) followed by vigorous vortexing
207 for 2 min. The cell suspensions were appropriately diluted and plated on respective agar plates

208 for determining the cell density. Total viable cells attached on surfaces were calculated and
209 expressed as CFU cm⁻² [24].

210 **2. 9. Statistical Analysis**

211 All the assays were carried out using minimum three biological replicates and the results are
212 expressed as mean \pm standard deviation. One-way analysis of variance (ANOVA) was performed
213 using SPSS version 17.0 (SPSS Inc., Chicago, IL, USA).

214 **3. Results**

215 **3. 1. MIC & MBC of planktonic cells**

216 Susceptibility of *S. aureus* and *E. coli* to capsaicin increased significantly ($p < 0.05$) in a
217 concentration dependent manner. The MIC of capsaicin inhibiting visual planktonic growth was
218 observed at 4 $\mu\text{g mL}^{-1}$ for *S. aureus* and *E. coli*. A 50% reduction in cell growth was observed at
219 concentrations of 128 $\mu\text{g mL}^{-1}$ [MIC₅₀] for both the bacterial strains (Figure 1a). In comparison,
220 a lower MIC value of 2 $\mu\text{g mL}^{-1}$ was observed for *C. albicans* and 50% inhibition of fungal
221 growth was observed at a lower concentration of 64 $\mu\text{g mL}^{-1}$ [MIC₅₀]. Analysis of minimum
222 fungicidal concentrations also revealed that capsaicin was more effective against the fungus *C.*
223 *albicans* with 100% growth inhibition achieved at 256 $\mu\text{g mL}^{-1}$ of capsaicin. The next most
224 susceptible organism among tested was *E. coli* in which, 100% inhibition was observed at 1024
225 $\mu\text{g mL}^{-1}$. However, *S. aureus* showed only 97.8% growth inhibition at the highest concentration
226 tested (1024 $\mu\text{g mL}^{-1}$).

227 **3. 2. Metabolic activity of planktonic cells**

228 Reduction of tetrazolium salt is a common method to assess metabolic activity of planktonic
229 cells which was assessed using sub-lethal concentrations of capsaicin (64 and 128 $\mu\text{g mL}^{-1}$).
230 XTT assay revealed 38% decrease in metabolic activity at 64 $\mu\text{g mL}^{-1}$ for *S. aureus*, 32% for *E.*
231 *coli* and 30% for *C. albicans*. The next increased sub-lethal concentration of 128 $\mu\text{g mL}^{-1}$ tested
232 revealed 57%, 45% and 57% reductions in *S. aureus*, *E. coli* and *C. albicans* metabolic activity,
233 respectively (Figure 2a). Reduced metabolic activity with increasing concentration of capsaicin
234 on planktonic cells may be one of the reasons for the observed mortality of planktonic cells.

235 **3. 3. Uptake of Propidium Iodide and membrane damage in planktonic cells**

236 Propidium iodide uptake of cells exposed to sub-lethal concentration of capsaicin (64 and 128 μg
237 mL^{-1}) showed increased membrane damage than respective controls (Figure 2b). A 3.6 fold
238 increase in RFU was observed with *S. aureus*, 1.4 fold with *E. coli* and 1.3 fold increases with *C.*
239 *albicans* at 64 $\mu\text{g mL}^{-1}$ capsaicin treatment compared to untreated controls. In comparison the
240 higher concentration of capsaicin (128 $\mu\text{g mL}^{-1}$) elicited an even higher response of 5.8, 3.7 and
241 2 fold increase in membrane permeability to PI with respective to *S. aureus*, *E. coli* and *C.*
242 *albicans*.

243 3. 4. MBIC and biofilm eradication concentrations

244 Compared to planktonic cells, the lowest concentration of capsaicin tested *viz*: 2 $\mu\text{g mL}^{-1}$ elicited
245 53% reduction in *S. aureus* biofilm formation and the next most susceptible organism was *C.*
246 *albicans* with 56% reduction at 8 $\mu\text{g mL}^{-1}$. In comparison higher concentrations of 64 $\mu\text{g mL}^{-1}$
247 was needed for *E. coli*. The biofilm eradication concentrations for total biofilm were much lower
248 than planktonic cells *viz*: 256 $\mu\text{g mL}^{-1}$ for *S. aureus*, 512 $\mu\text{g mL}^{-1}$ for *E. coli* and 128 $\mu\text{g mL}^{-1}$ for
249 *C. albicans* (Figure 1b). Microscopic analysis revealed the dense and confluent architecture of *S.*
250 *aureus* and *E. coli* control biofilms. *C. albicans* control biofilm was composed of highly virulent
251 filamentous hyphae, whereas capsaicin ($>128 \mu\text{g mL}^{-1}$) abrogated hyphal forms and more yeast
252 forms were observed (Figure 3). Steady increase in red cell population was observed right from
253 64 $\mu\text{g mL}^{-1}$ of capsaicin treatment, which indicates the increase of dead cells or cells with
254 compromised membrane integrity stained by PI and complete inhibition of biofilm was observed
255 at concentrations of 512 and 1024 $\mu\text{g mL}^{-1}$.

256 3. 5. Inhibition of Biofilm formation on Capsaicin loaded PDMS surfaces

257 Incorporation of capsaicin into PDMS (0.5%) inhibited biofilm formation of all three test strains
258 (Figure 4). An 87% reduction in viable counts was observed between (control $5 \times 10^6 \text{ CFU cm}^{-2}$)
259 and capsaicin loaded surfaces ($6 \times 10^5 \text{ CFU cm}^{-2}$) for *S. aureus*. Similarly 92% reduction was
260 observed between plain PDMS ($5 \times 10^5 \text{ CFU cm}^{-2}$) and capsaicin loaded PDMS ($4 \times 10^4 \text{ CFU}$
261 cm^{-2}). Control *C. albicans* colonized PDMS surfaces with a magnitude of $5 \times 10^4 \text{ CFU cm}^{-2}$,
262 whereas 95% reduction was observed in capsaicin infused PDMS ($2 \times 10^3 \text{ CFU cm}^{-2}$).

263 4. Discussion

264 Biofilms contribute to 50-70% of device associated infections [25]. Biofilm mode offers
265 10 to 1000 times more resistance to antimicrobials compared to their planktonic counterparts
266 which make biofilms hard to eradicate, once formed. Biofilm infections associated with
267 implants, serve as a reservoir of pathogens; cause tissue destruction, dysfunction of device
268 resulting in morbidity or fatality of infected patients [26]. Elimination of biofilm formation on
269 implants and biomaterials is a major challenge. Predominantly the common implant associated
270 infections are caused by *S. aureus*, *S. epidermidis*, *E. coli*, *Pseudomonas aeruginosa*, *C.*
271 *albicans*, *Enterococcus faecalis*, *Proteus mirabilis* [27]. Gram positive cocci, Gram negative
272 rods and *C. albicans* respectively constituted 77%, 15% and 8% of all infections caused due to
273 ureteral stents inserted for a period ranging from 5-128 days [28]. For a surgical implanted
274 device to be successful, tissue integration should occur prior to bacterial adhesion, thereby
275 inhibiting biofilm formation is crucial which usually happens in the first 24 h of implantation.
276 Whereas in the case of non-surgical indwelling medical devices, such as urinary catheters, the
277 source of contamination may originate from the point of insertion around the catheters [29].
278 Implant associated infections caused by biofilms are hard to eradicate and often results in
279 surgical removal of the implanted devices as the infection persists for long time periods [6].
280 Hence current research focus has been aimed at prevention of biofilm formation and infection
281 following implantation by developing methods for loading or embedding biomaterial surface
282 with antimicrobial substances. These techniques offer more advantages over systemic drug
283 delivery as the antimicrobials are present within the implant and offer sustained delivery of a low
284 dose antimicrobial for prolonged periods until tissue integration is complete [30].

285 The microbicidal action of capsaicin on all the three microbes assessed by Live/Dead
286 assay revealed membrane damage at sub lethal concentrations of 64 and 128 $\mu\text{g mL}^{-1}$. Cell
287 membrane is an important component involved in maintaining cell architecture as well as
288 protection from environmental stressors. Propidium iodide (PI), a fluorescent probe, binds to
289 nucleic acids producing a red fluorescence in cells with compromised cell membranes. Capsaicin
290 treated cells were more permeable to uptake of propidium iodide suggesting membrane damage
291 which is in accordance with earlier observations for the compound [15]. In addition, the XTT
292 assay revealed that capsaicin also reduces the metabolic activity of all the strains tested. At sub-
293 lethal concentration of 128 $\mu\text{g mL}^{-1}$, XTT assay detected 57% reduction of metabolic activity in
294 *S. aureus* and 45% in *E. coli* and 57% in *C. albicans*. This well explains the fractional

295 occurrence of planktonic and biofilm growth at sub-lethal concentrations. The fraction of
296 metabolically active cells could grow and repopulate at sub-lethal concentrations, and hence
297 there is a need for bactericidal concentrations which are found to be higher ($1024 \mu\text{g mL}^{-1}$).
298 Biomass production has also been shown to influence the metabolic activity of the population
299 and hence in the present XTT assays cell density was maintained similar to differentiate effects
300 of capsaicin on reduction of metabolic activity [31]. Similar observations were reported by Peters
301 et al., (2013) for ethanol on mono and polymicrobial biofilms of *S. aureus* and *C. albicans* [32].

302 A concentration dependent increase in biofilm inhibition by capsaicin was observed for
303 all the three strains investigated. Complete biofilm eradication concentrations varied with
304 different microbial species like *C. albicans* requires less concentration ($128 \mu\text{g mL}^{-1}$) compared
305 to *S. aureus* ($256 \mu\text{g mL}^{-1}$) and *E. coli* found to be the most tolerant requiring higher
306 concentrations of capsaicin ($512 \mu\text{g mL}^{-1}$). Such high concentration of capsaicin (7 mM) was
307 required in earlier report [18] for reducing the adherence of *E. coli*, wherein the present study 1.6
308 mM capsaicin effectively controlled *E. coli*. This is attributed to the difference in inoculum size.
309 Apart from reducing biofilm formation, capsaicin compromises membrane integrity of attached
310 cells which is evident from the increased proportion of PI stained microcolonies present in
311 capsaicin treated samples. Reduced metabolic activity of cells treated with capsaicin will also
312 significantly contribute to the reduction of biofilm mass. Apart from this, capsaicin is known to
313 inhibit various biofilm components such as protein, carbohydrate and DNA which are key
314 components of EPS [18]. In addition, capsaicin has been found to inhibit the release of DNase
315 enzyme in *S. aureus* [33].

316 In the present work embedding / loading of capsaicin in PDMS polymer matrix and
317 evaluating its antimicrobial efficacy in inhibiting biofilm formation of the nosocomial pathogens
318 *S. aureus*, *E. coli* and *C. albicans* was evaluated. Plain PDMS surfaces were colonized by $4.8 \times$
319 10^6 CFU cm^{-2} for *S. aureus*; 5.1×10^5 cfu cm^{-2} for *E. coli* and 5.2×10^4 cfu cm^{-2} for *C. albicans*
320 after 24 h incubation. In comparison, nearly a one log (~90%) reduction of viable cells on
321 capsaicin loaded PDMS (0.5%), was observed for all three strains with 87% reduction with *S.*
322 *aureus*, 92% for *E. coli* and 95% for *C. albicans*. The optimum concentrations of capsaicin
323 required for complete biofilm inhibition of all three strains in the present study was observed to
324 be $512 \mu\text{g mL}^{-1}$, however membrane damage occurred at even much lower concentration of 128
325 $\mu\text{g mL}^{-1}$ for all the three strains. PDMS surfaces were infused with ~10 fold higher concentration

326 of capsaicin (0.5% w/v) considering the thickness of the film and immiscibility of capsaicin.
327 Capsaicin incorporated PDMS exhibited similar mechanical properties as that of control.
328 Previous study by Al-Juhani and Newby (2014) has extensively revealed the indifference in
329 curing behaviour, bulk and surface properties of PDMS *viz*; water contact angle, surface
330 roughness while incorporating low content of capsaicin (up to 1%) [34]. Considering the fact, in
331 the present study relatively insignificant capsaicin (<1%) was included which may not affect the
332 property of silicone polymer and the manifested antimicrobial activities are attributed to the
333 infused capsaicin. Similarly, inhibition of *S. aureus* on PDMS-PEEK implant surfaces has been
334 demonstrated by incorporating Ag (bioactivity) doped TiO₂ (biocompatibility) nanoparticles into
335 the PDMS matrix where complete biofilm inhibition was dependent on the amount of Ag doped
336 TiO₂ nanoparticles [35]. Nano-patterned PDMS surfaces inhibited biofilm formation of both *E.*
337 *coli* (57%) and *S. aureus* (79.2%) and showed increased fibroblast and endothelial cell adhesion
338 which reiterates the biocompatibility of PDMS matrix [20]. Capsaicin is known to inhibit NorA
339 efflux pumps of *S. aureus* and potentiate ciprofloxacin that shows the combinatorial efficacy of
340 capsaicin [16]. Incorporation of capsaicin into carbopol gels decreased the MIC by 50%
341 compared to plain capsaicin for *C. albicans*, *S. aureus* and *E. coli* [13]. These show the plausible
342 way of incorporating capsaicin into biomaterials along with other antimicrobials which can help
343 in the fight against antimicrobial resistance.

344 Besides inhibiting the adhesion of biofilm forming strains on PDMS, capsaicin exhibited
345 effective contact killing of attached microbes. Similar contact killing of attached cells on
346 functionalized PDMS has also been reported [36]. In the present study capsaicin-PDMS matrix
347 exhibited broad spectrum antibiofilm activity which is a prerequisite for any implant material.
348 Such broad spectrum antimicrobial activity of PDMS nanocomposites have been achieved by
349 incorporating nanoparticles [37,38]; polyimidazolium and covalent bonding of poly
350 (sulfo/carboxy betaine) with PDMS [2]. However one drawback of these approaches for *in situ*
351 applications is their biocompatibility issues as most of the nanoparticles and chemical moieties
352 exhibit cytotoxicity. In comparison, capsaicin is a safe, biodegradable and biocompatible
353 compound which can impart antimicrobial property to any surface which requires
354 biocompatibility.

355 Capsaicin loaded PDMS exhibited complete biofilm inhibition of the all three strains with
356 a loading of 0.5% (w/v) whereas aqueous suspensions of capsaicin as such required a much

357 lesser concentration. This may be attributed to the slow release of capsaicin incorporated in the
358 porous PDMS polymer matrix which will have sustained release of capsaicin for extended period
359 of time. Studies on leaching of capsaicin from PDMS matrix have revealed around 60% retention
360 of original capsaicin mass incorporated into PDMS coatings after 30 days of exposure [34]. This
361 will render a prolonged liberation of capsaicin to the microenvironment which can offer
362 sustained antimicrobial property to the surface. Despite of excellent antimicrobial and
363 biocompatible properties, capsaicin-PDMS surfaces lack uniformity in capsaicin distribution due
364 to the immiscibility of capsaicin with PDMS. This forms heterogeneity in capsaicin aggregates
365 which affects uniform distribution and release. Future research should be focused to develop
366 silicones incorporated with capsaicin nano-emulsions that can help in uniform distribution as
367 well as effective and controlled release.

368 **5. Conclusion**

369 The present study provides optimal concentrations of capsaicin required for broad spectrum
370 antibiofilm activity against selected Gram positive, negative and fungal pathogens. Capsaicin
371 imparted antimicrobial property to PDMS surfaces by causing membrane damage and reducing
372 metabolic activity of bacterial and fungal pathogens. Inherent antibiofilm property of capsaicin
373 loaded PDMS, will serve as a potential biomaterial that can be helpful in tackling microbial
374 infections.

375 **Acknowledgement**

376 The authors gratefully acknowledge the support extended by Dr. T.V. Krishna Mohan, Head-
377 WSCD.

378 **Declaration of Competing Interest**

379 None to declare

380 **References:**

- 381 1. Lam M, Migonney V, Falentin-Daudre C: **Review of silicone surface modification techniques and**
382 **coatings for antibacterial/antimicrobial applications to improve breast implant surfaces.** *Acta*
383 *Biomaterialia* 2021, **121**:68-88.

- 384 2. Armugam A, Teong SP, Lim DSW, Chan SP, Yi G, Yew DS, Beh CW, Zhang Y: **Broad spectrum**
385 **antimicrobial PDMS-based biomaterial for catheter fabrication.** *Biomaterials Research* 2021,
386 **25:33.**
- 387 3. Lou Y, Schapman D, Mercier D, Alexandre S, Burel F, Thebault P, Kébir N: **Self-disinfecting PDMS**
388 **surfaces with high quaternary ammonium functionality by direct surface photoinitiated**
389 **polymerization of vinylbenzyl dimethylbutylammonium chloride.** *European Polymer Journal*
390 2021, **152:110473.**
- 391 4. Donlan RM, Costerton JW: **Biofilms: survival mechanisms of clinically relevant microorganisms.** *Clin*
392 *Microbiol Rev* 2002, **15:167-193.**
- 393 5. Arias SL, Devorkin J, Civantos A, Allain JP: **Escherichia coli Adhesion and Biofilm Formation on**
394 **Polydimethylsiloxane are Independent of Substrate Stiffness.** *Langmuir* 2021, **37:16-25.**
- 395 6. Zimmerli W, Moser C: **Pathogenesis and treatment concepts of orthopaedic biofilm infections.** *FEMS*
396 *Immunol Med Microbiol* 2012, **65:158-168.**
- 397 7. Daniels AU: **Silicone breast implant materials.** *Swiss Med Wkly* 2012, **142:w13614.**
- 398 8. Sendi P, Frei R, Maurer TB, Trampuz A, Zimmerli W, Graber P: **Escherichia coli variants in**
399 **periprosthetic joint infection: diagnostic challenges with sessile bacteria and sonication.** *J Clin*
400 *Microbiol* 2010, **48:1720-1725.**
- 401 9. Cavalheiro M, Teixeira MC: **Candida Biofilms: Threats, Challenges, and Promising Strategies.** 2018, **5.**
- 402 10. De Prijck K, De Smet N, Honraet K, Christiaen S, Coenye T, Schacht E, Nelis HJ: **Inhibition of Candida**
403 **albicans biofilm formation by antimycotics released from modified polydimethyl siloxane.**
404 *Mycopathologia* 2010, **169:167-174.**
- 405 11. Mendes RM, Francisco AP, Carvalho FA, Dardouri M, Costa B, Bettencourt AF, Costa J, Gonçalves L,
406 Costa F, Ribeiro IAC: **Fighting S. aureus catheter-related infections with sophorolipids: Electing**
407 **an antiadhesive strategy or a release one?** *Colloids and Surfaces B: Biointerfaces* 2021,
408 **208:112057.**
- 409 12. Hayman M, Kam PCA: **Capsaicin: A review of its pharmacology and clinical applications.** *Current*
410 *Anaesthesia & Critical Care* 2008, **19:338-343.**
- 411 13. Goci E, Haloci E, Di Stefano A, Chiavaroli A, Angelini P, Miha A, Cacciatore I, Marinelli L: **Evaluation of**
412 **In Vitro Capsaicin Release and Antimicrobial Properties of Topical Pharmaceutical**
413 **Formulation.** *Biomolecules* 2021, **11.**
- 414 14. Agarwal P, Das C, Dias O, Shanbhag T: **Antimicrobial property of Capsaicin.** *International research*
415 *journal of biological sciences* 2017, **6:7-11.**
- 416 15. Marini E, Magi G, Mingoia M, Pugnali A, Facinelli B: **Antimicrobial and Anti-Virulence Activity of**
417 **Capsaicin Against Erythromycin-Resistant, Cell-Invasive Group A Streptococci.** *Front Microbiol*
418 2015, **6:1281.**
- 419 16. Kalia NP, Mahajan P, Mehra R, Nargotra A, Sharma JP, Koul S, Khan IA: **Capsaicin, a novel inhibitor of**
420 **the NorA efflux pump, reduces the intracellular invasion of Staphylococcus aureus.** *J*
421 *Antimicrob Chemother* 2012, **67:2401-2408.**
- 422 17. Swetha TK, Vikraman A, Nithya C, Hari Prasath N, Pandian SK: **Synergistic antimicrobial combination**
423 **of carvacrol and thymol impairs single and mixed-species biofilms of Candida albicans and**
424 **Staphylococcus epidermidis.** *Biofouling* 2020, **36:1256-1271.**
- 425 18. Silva HRA, de Souza GM, Fernandes JD, Constantino CJL, Winkelstroter LK: **Unravelling the effects of**
426 **the food components ascorbic acid and capsaicin as a novel anti-biofilm agent against**
427 **Escherichia coli.** *Journal of Food Science and Technology* 2020, **57:1013-1020.**
- 428 19. He G, Liu Y, Liu W, Dong L, Yu L, Wang L: **A highly antifouling and eco-friendly hydrogel coating**
429 **based on capsaicin derivative -functionalized polymer.** *Journal of Cleaner Production* 2023,
430 **429:139538.**

- 431 20. Liu L, Ercan B, Sun L, Ziemer KS, Webster TJ: **Understanding the Role of Polymer Surface Nanoscale**
432 **Topography on Inhibiting Bacteria Adhesion and Growth.** *ACS Biomaterials Science &*
433 *Engineering* 2016, **2**:122-130.
- 434 21. Clinical, Laboratory Standards Institute %J CLSI supplement M60. Wayne PC: **Performance standards**
435 **for antifungal susceptibility testing of yeasts.** 2017.
- 436 22. Padmavathi AR, Abinaya B, Pandian SK: **Phenol, 2,4-bis(1,1-dimethylethyl) of marine bacterial origin**
437 **inhibits quorum sensing mediated biofilm formation in the uropathogen *Serratia marcescens*.**
438 *Biofouling* 2014, **30**:1111-1122.
- 439 23. Padmavathi AR, Sriyutha Murthy P, Das A, Nishad PA, Pandian R, Rao TS: **Copper oxide nanoparticles**
440 **as an effective anti-biofilm agent against a copper tolerant marine bacterium, *Staphylococcus***
441 ***lentus*.** *Biofouling* 2019, **35**:1007-1025.
- 442 24. Padmavathi AR, Murthy PS, Das A, Veeramani P, Rao TS: **Inorganic nanoparticle embedded**
443 **Polydimethyl siloxane nanocomposites for biofouling mitigation.** *Surfaces and Interfaces* 2021,
444 **25**:101171.
- 445 25. Zhu Z, Wang Z, Li S, Yuan X: **Antimicrobial strategies for urinary catheters.** *J Biomed Mater Res A*
446 2019, **107**:445-467.
- 447 26. Hall-Stoodley L, Costerton JW, Stoodley P: **Bacterial biofilms: from the natural environment to**
448 **infectious diseases.** *Nat Rev Microbiol* 2004, **2**:95-108.
- 449 27. Fernandes A, Dias M: **The Microbiological Profiles of Infected Prosthetic Implants with an Emphasis**
450 **on the Organisms which Form Biofilms.** *J Clin Diagn Res* 2013, **7**:219-223.
- 451 28. Reid G, Denstedt JD, Kang YS, Lam D, Nause C: **Microbial adhesion and biofilm formation on**
452 **ureteral stents in vitro and in vivo.** *J Urol* 1992, **148**:1592-1594.
- 453 29. Veerachamy S, Yarlagadda T, Manivasagam G, Yarlagadda PK: **Bacterial adherence and biofilm**
454 **formation on medical implants: a review.** *Proc Inst Mech Eng H* 2014, **228**:1083-1099.
- 455 30. Wu P, Grainger DW: **Drug/device combinations for local drug therapies and infection prophylaxis.**
456 *Biomaterials* 2006, **27**:2450-2467.
- 457 31. Alonso B, Lucio J, Pérez-Granda MJ, Cruces R, Sánchez-Carrillo C, Bouza E, Guembe M: **Does biomass**
458 **production correlate with metabolic activity in *Staphylococcus aureus*?** *J Microbiol Methods*
459 2016, **131**:110-112.
- 460 32. Peters BM, Ward RM, Rane HS, Lee SA, Noverr MC: **Efficacy of ethanol against *Candida albicans* and**
461 ***Staphylococcus aureus* polymicrobial biofilms.** *Antimicrob Agents Chemother* 2013, **57**:74-82.
- 462 33. Zarringhalam M, Zarringhalam J, Shadnoush M, Safaeyan F, Tekieh E: **Inhibitory Effect of Black and**
463 **Red Pepper and Thyme Extracts and Essential Oils on Enterohemorrhagic *Escherichia coli* and**
464 **DNase Activity of *Staphylococcus aureus*.** *Iran J Pharm Res* 2013, **12**:363-369.
- 465 34. Al-Juhani A, Zhang Newby B-m: **Assessments of Capsaicin Incorporated Silicone Rubber as**
466 **Antifouling Coatings.** *Journal of Rubber Research* 2014, **17**:173-186.
- 467 35. Tran N, Kelley MN, Tran PA, Garcia DR, Jarrell JD, Hayda RA, Born CT: **Silver doped titanium oxide–**
468 **PDMS hybrid coating inhibits *Staphylococcus aureus* and *Staphylococcus epidermidis* growth**
469 **on PEEK.** *Materials Science and Engineering: C* 2015, **49**:201-209.
- 470 36. Dong JJ, Muszanska A, Xiang F, Falkenberg R, van de Belt-Gritter B, Loontjens T: **Contact Killing of**
471 **Gram-Positive and Gram-Negative Bacteria on PDMS Provided with Immobilized**
472 **Hyperbranched Antibacterial Coatings.** *Langmuir* 2019, **35**:14108-14116.
- 473 37. Padmavathi AR, P SM, Das A, Priya A, Sushmitha TJ, Pandian SK, Toleti SR: **Impediment to growth**
474 **and yeast-to-hyphae transition in *Candida albicans* by copper oxide nanoparticles.** *Biofouling*
475 2020, **36**:56-72.
- 476 38. Sankar GG, Murthy PS, Das A, Sathya S, Nankar R, Venugopalan VP, Doble M: **Polydimethyl siloxane**
477 **based nanocomposites with antibiofilm properties for biomedical applications.** *J Biomed*
478 *Mater Res B Appl Biomater* 2017, **105**:1075-1082.

479

480 **Figure legends**

481 **Figure 1. (a)** Antibacterial and **(b)** antibiofilm activity of capsaicin against *Staphylococcus*
482 *aureus*, *Escherichia coli* and *Candida albicans*. * indicates $p \leq 0.05$, ** indicates $p \leq 0.005$, ***
483 indicates $p \leq 0.001$.

484 **Figure 2.** Effect of sub-MIC of capsaicin on metabolic activity **(a)** and membrane integrity **(b)** of
485 *S. aureus*, *E. coli* and *C. albicans*. * indicates $p \leq 0.05$, ** indicates $p \leq 0.005$, *** indicates
486 $p \leq 0.001$.

487 **Figure 3.** Effect of various concentrations of capsaicin ($\mu\text{g mL}^{-1}$) on the biofilm formation of *S.*
488 *aureus*, *E. coli* and *C. albicans*.

489 **Figure 4.** Biofilms of *S. aureus*, *E. coli* and *C. albicans* formed on plain PDMS and capsaicin
490 (0.5% w/v) incorporated PDMS.

491

492